Table 3.
Summary of the Role of the −16kb Enhancer in Fgf23 Regulation in Response to Acute Inflammation and Kidney Disease
Fgf23 mRNA levels | |||||||||
---|---|---|---|---|---|---|---|---|---|
Bone | Bone marrow | Thymus | Spleen | Kidney | Intestine | Lung | Liver | iFGF23 Plasma | |
IL‐1β | + | + | + | + | + | + | + | + | + |
Tnfα | + | + | + | + | + | + | + | – | + |
LPS | + | + | + | + | – | + | + | + | + |
Oxalate diet | + | UD | + | x | + | UD | UD | x | + |
A comparison of the results of Fgf23 mRNA regulation by inflammatory cytokines and CKD in different tissues with levels in the circulation as observed in Figs. 3, 4, 5, 6, 7.
+ = −16kb enhancer plays a role in the Fgf23 induction; − = −16kb enhancer does not play a role in Fgf23 induction; X = Fgf23 is not regulated; UD = Fgf23 levels were not measured.